Clinical Trial Update: Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating liposomal irinotecan for advanced refractory gastric cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Gastric Cancer | Phase 2 | Status: NOT_YET_RECRUITING